Lonza Group AG
SWB:LO3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
L
|
Lonza Group AG
SWB:LO3
|
CH |
Intrinsic Value
The intrinsic value of 
Lonza Group AG (LO3) under the Base Case is 238.5 EUR per share.
Compared with the current market price of 294 EUR, the stock appears
Overvalued by 19% .
The intrinsic value is the average of valuations using the DCF method and multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Lonza Group Does
Lonza Group AG is a life sciences company that makes and supplies ingredients, materials, and manufacturing services used in medicines and other health products. It does not sell to ordinary consumers; instead, it works behind the scenes for drug makers, biotech companies, and healthcare customers that need help developing or producing complex products.
- Headquarters
- Switzerland CH
- Employees
- 20 000
- IPO date
- Apr 3, 2002
Lonza Group has no economic moat
Rival manufacturers can offer drugmakers alternative production facilities and technical expertise, so Lonza cannot rely on its size alone to keep competitors out. Its established capabilities help it compete, but do not give it exclusive access to customers or drug-manufacturing markets.
Read the full moat analysis
Earnings Waterfall
Lonza Group AG
The intrinsic value for Lonza Group AG (LO3) under the Base Case is 238.5 EUR.
Compared with the current market price of 294 EUR, the stock appears Overvalued by 19% .
